MétaCan
Menu
Back to cohort
Record W3158922343 · doi:10.1038/s41467-021-22625-y

A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia

2021· article· en· W3158922343 on OpenAlexafffund
Roderick Docking, Jeremy Parker, Martin Jädersten, Gerben Duns, Linda Chang, Jihong Jiang, Jessica A. Pilsworth, Lucas Swanson, Simon K. Chan, Readman Chiu, Ka Ming Nip, Angela Mo, Xuan Wang, Sergio Martínez-Høyer, Ryan J. Stubbins, Karen Mungall, Andrew J. Mungall, Richard A. Moore, Steven J.M. Jones, İnanç Birol, Marco A. Marra, Donna E. Hogge, Aly Karsan

Bibliographic record

VenueNature Communications · 2021
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsVancouver General HospitalCanada's Michael Smith Genome Sciences CentreUniversity of British Columbia
FundersBC Cancer AgencyNational Cancer InstituteBC Cancer FoundationTerry Fox Research InstituteGenome British ColumbiaNational Human Genome Research InstituteLeukemia and Lymphoma Society of CanadaKnight Cancer Institute, Oregon Health and Science UniversityOregon Health and Science UniversityProvincial Health Services AuthorityLeukemia and Lymphoma Society
KeywordsMyeloid leukemiaTranscriptomeRisk stratificationSelection (genetic algorithm)MedicineComputational biologyLeukemiaMyeloidStratification (seeds)BioinformaticsIntensive care medicineOncologyBiologyComputer scienceCancer researchInternal medicineGeneticsGeneArtificial intelligenceGene expression

Abstract

fetched live from OpenAlex

As more clinically-relevant genomic features of myeloid malignancies are revealed, it has become clear that targeted clinical genetic testing is inadequate for risk stratification. Here, we develop and validate a clinical transcriptome-based assay for stratification of acute myeloid leukemia (AML). Comparison of ribonucleic acid sequencing (RNA-Seq) to whole genome and exome sequencing reveals that a standalone RNA-Seq assay offers the greatest diagnostic return, enabling identification of expressed gene fusions, single nucleotide and short insertion/deletion variants, and whole-transcriptome expression information. Expression data from 154 AML patients are used to develop a novel AML prognostic score, which is strongly associated with patient outcomes across 620 patients from three independent cohorts, and 42 patients from a prospective cohort. When combined with molecular risk guidelines, the risk score allows for the re-stratification of 22.1 to 25.3% of AML patients from three independent cohorts into correct risk groups. Within the adverse-risk subgroup, we identify a subset of patients characterized by dysregulated integrin signaling and RUNX1 or TP53 mutation. We show that these patients may benefit from therapy with inhibitors of focal adhesion kinase, encoded by PTK2, demonstrating additional utility of transcriptome-based testing for therapy selection in myeloid malignancy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.050
GPT teacher head0.375
Teacher spread0.325 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations104
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueNature CommunicationsSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207